Putnam Investments’s Blueprint Medicines BPMC Stock Holding History

Putnam Investments’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-173,910	Closed	-$11.5M	–	1142
2022 Q3	$11.5M	Buy	+173,910	New	+$11.2M	0.02%	264
2021 Q2	–	Sell	-88,700	Closed	-$8.62M	–	793
2021 Q1	$8.62M	Buy	+88,700	New	+$8.86M	0.01%	400
2020 Q2	–	Sell	-104,400	Closed	-$6.11M	–	878
2020 Q1	$6.11M	Buy	+104,400	New	+$6.72M	0.02%	407
2019 Q4	–	Sell	-29,284	Closed	-$2.15M	–	895
2019 Q3	$2.15M	Sell	29,284 -11,616	-28%	-$1M	﹤0.01%	708
2019 Q2	$3.86M	Buy	+40,900	New	+$3.38M	0.01%	589
2017 Q1	–	Sell	-98,700	Closed	-$2.77M	–	1252
2016 Q4	$2.77M	Hold	98,700	–	–	0.01%	759
2016 Q3	$2.93M	Sell	98,700 -389,522	-80%	-$9.68M	0.01%	739
2016 Q2	$9.89M	Buy	488,222 +25,225	+5%	+$458K	0.02%	417
2016 Q1	$8.36M	Buy	462,997 +119,220	+35%	+$2.07M	0.02%	484
2015 Q4	$9.05M	Buy	343,777 +244,477	+246%	+$5.5M	0.02%	485
2015 Q3	$2.12M	Hold	99,300	–	–	﹤0.01%	979
2015 Q2	$2.63M	Buy	+99,300	New	+$2.84M	0.01%	971

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Putnam Investments's BPMC Position: Q4 2022 in Review

Putnam Investments sold out of Blueprint Medicines (BPMC) in Q4 2022, closing a stake of 173,910 shares — an estimated $11.5M sold.

Putnam Investments first reported a position in BPMC in Q2 2015 and held it in 12 quarters. The position peaked at $11.5M in Q3 2022. 223 funds tracked by Wall St. Rank hold BPMC as of Q4 2022.

Putnam Investments reported no remaining Blueprint Medicines position as of Q4 2022 after selling out during the quarter.
Putnam Investments sold 173,910 Blueprint Medicines shares in Q4 2022, an estimated $11.5M.
Putnam Investments first reported a position in Blueprint Medicines in Q2 2015 and held it in 12 quarters.
Putnam Investments's Blueprint Medicines position peaked at $11.5M in Q3 2022.
223 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2022.

Based on Putnam Investments's 13F filing for Q4 2022, filed 14 Feb 2023.